Arnatar Therapeutics has launched with $52M in VC funding to create a dual-modality RNA platform. Its first target is Alagille syndrome (ALGS).

Arnatar Details

• Innovative Nucleic Acid drug development
• Chinese origin, founded in 2022 using $14.45M from Apricot Capital.
• Operated in Stealth mode until Series A in 2025
• HQ in San Diego, CA
  Source: CapitalIQ.com

Series A Funding

The funding was led by Eight Roads global venture group and 3E Bioventures.

Additional investors: F-Prime Capital (US), Beijing Legend Star (China), Gaorong Ventures (China), Hongsheng Capital (China). (Source: CapitalIQ.com)

What is ALGS?

The accumulation of bile in the liver because there aren’t enough bile ducts to drain it. (Source)

• It is caused by a mutation in the JAG1 gene
• About 50% of ALGS patients have acquired it through a spontaneous mutation
• ALGS can also be inherited. If one of your parents has ALGS, you have a 50% chance of getting it.
• Symptoms: yellow skin or eyes, itchy skin, delayed growth, skin bumps, heart murmur

How is Arnatar’s RNA dual modality?

Arnatar’s therapy combines the following:

• siRNA that silences target mRNAs
• Antisense oligonucleotides that bind with mRNA and promote protein synthesis.